Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMPEL NEUROPHARMA, INC.

(IMPL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Impel NeuroPharma : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (Form 8-K)

10/01/2021 | 04:13pm EST

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

As previously disclosed, Impel NeuroPharma Inc., (the "Company") entered into a loan and security agreement (the "Agreement"), dated July 2, 2021 (the "Closing Date"), with Oxford Finance LLC ("Oxford"), as the collateral agent and a lender, and Silicon Valley Bank ("SVB"), as lender (together with Oxford, the "Lenders") pursuant to which a term loan of up to an aggregate principal amount of $50.0 million was made available to the Company. Pursuant to the Agreement, a $20.0 million term loan was previously funded on the Closing Date, leaving two additional term loan advances of $10.0 million and $20.0 million available under the Agreement after the Closing Date.

On September 30, 2021, the Company elected to draw down the second $10.0 million term loan advance under the Agreement (the "Term B Loan"). Immediately following this $10.0 million drawdown, $20.0 million of borrowing capacity remained available under the Agreement, subject to the terms and conditions set forth therein.

In addition, in connection with the Term B Loan, the Company issued the Lenders warrants to purchase 23,166 shares of the Company's common stock at an exercise price per share of $12.95 (the "Warrants"). The Warrants will be exercisable for 10 years from the date of issuance.

The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement which was filed as Exhibit 10.4 to the Quarterly Report on Form 10-Q filed by the Company on August 16, 2021.

Unregistered Sales of Equity Securities.

The information set forth in Item 2.03 above regarding the Warrants is incorporated by reference into this Item 3.02. The issuance of the Warrants were, and the issuance of the shares of the Company's common stock underlying the Warrants will be, made in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.

3

Disclaimer

Impel Neuropharma Inc. published this content on 01 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 October 2021 20:12:09 UTC.


ę Publicnow 2021
All news about IMPEL NEUROPHARMA, INC.
11/16Wedbush Lifts Price Target on Impel NeuroPharma to $40 From $39; Outperform Rating Kept
MT
11/15IMPEL NEUROPHARMA : Announces THIRD Quarter 2021 Financial Results and Provides CORPORATE ..
PU
11/15IMPEL NEUROPHARMA INC Management's Discussion and Analysis of Financial Condition and ..
AQ
11/15Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate..
AQ
11/09Impel NeuroPharma to Present at the Guggenheim Securities 3rd Annual Neuro/Immunology C..
AQ
11/08Impel NeuroPharma to Report Third Quarter 2021 Financial Results on Monday, November 15..
AQ
11/08Certain Common Stock of Impel NeuroPharma, Inc. are subject to a Lock-Up Agreement Endi..
CI
11/08Certain Options of Impel NeuroPharma, Inc. are subject to a Lock-Up Agreement Ending on..
CI
11/08Certain Warrants of Impel NeuroPharma, Inc. are subject to a Lock-Up Agreement Ending o..
CI
10/20Certain Stock Options of Impel NeuroPharma, Inc. are subject to a Lock-Up Agreement End..
CI
More news
Analyst Recommendations on IMPEL NEUROPHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 1,72 M - -
Net income 2021 -72,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,14x
Yield 2021 -
Capitalization 215 M 215 M -
Capi. / Sales 2021 125x
Capi. / Sales 2022 5,73x
Nbr of Employees 59
Free-Float 97,5%
Chart IMPEL NEUROPHARMA, INC.
Duration : Period :
Impel NeuroPharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMPEL NEUROPHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 9,32 $
Average target price 48,33 $
Spread / Average Target 419%
EPS Revisions
Managers and Directors
Adrian Adams Chairman, President & Chief Executive Officer
John Harold Leaman Chief Financial & Business Officer
John D. Hoekman Chief Technology & Development Officer
Meghan Swardstrom Vice President-Clinical Development & Operations
Stephen Bevan Shrewsbury Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
IMPEL NEUROPHARMA, INC.0.00%215
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.81%24 431